Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase

Amanda K. Rudman Spergel, Ivan T. Lee, Kindra Koslovsky, Kristi Schaefers, Andrei Avanesov, Douglas K. Logan, John Hemmersmeier, David Ensz, Daniel Stadlbauer, Bo Hu, Alicia Pucci, Jignesh Vakil, Robert Paris, Jintanat Ananworanich and Raffael Nachbagauer ()
Additional contact information
Amanda K. Rudman Spergel: Inc.
Ivan T. Lee: Inc.
Kindra Koslovsky: Inc.
Kristi Schaefers: Inc.
Andrei Avanesov: Inc.
Douglas K. Logan: Velocity Clinical Research
John Hemmersmeier: CCT Research
David Ensz: Meridian Clinical Research
Daniel Stadlbauer: Inc.
Bo Hu: Inc.
Alicia Pucci: Inc.
Jignesh Vakil: Inc.
Robert Paris: Inc.
Jintanat Ananworanich: Inc.
Raffael Nachbagauer: Inc.

Nature Communications, 2025, vol. 16, issue 1, 1-9

Abstract: Abstract Current influenza vaccines induce immune responses to hemagglutinin (HA), a surface glycoprotein of seasonal influenza viruses, but have suboptimal effectiveness. mRNA vaccines may improve protection by targeting additional antigens such as neuraminidase (NA), for which immune responses independently correlate with protection. In this phase 1/2 trial (NCT05333289), healthy adults 18–75 years were randomly assigned to receive different doses of mRNA-1020 or mRNA-1030 (encoding HA and NA at different ratios), mRNA-1010 (encoding HA), or a licensed active comparator (recombinant HA). Primary endpoints were safety and reactogenicity, and HA and NA antibody responses against vaccine-matched influenza strains. Most common local and systemic solicited ARs were injection site pain and fatigue. There were no vaccine-related serious adverse events nor significant associated safety concerns through 181 days. mRNA-1020 and mRNA-1030 elicited high HA-specific immune responses and induced NA-specific immune responses with no additional reactogenicity at equivalent dose levels beyond an mRNA-based, HA-only–containing vaccine.

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-025-60938-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:16:y:2025:i:1:d:10.1038_s41467-025-60938-4

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-025-60938-4

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().